GSK PLC SP. ADR/2 NEW (F:GS70) — Stock Price
GSK PLC SP. ADR/2 NEW (F:GS70) is currently trading at €47.20 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €31.00 and €51.50. This page tracks GSK PLC SP. ADR/2 NEW's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see GSK PLC SP. ADR/2 NEW market capitalisation.
GSK PLC SP. ADR/2 NEW (GS70) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GSK PLC SP. ADR/2 NEW's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
GSK PLC SP. ADR/2 NEW Income Statement — Revenue, Profit & Earnings by Year
GSK PLC SP. ADR/2 NEW's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €32.67 Billion | €31.38 Billion | €30.33 Billion | €29.32 Billion | €24.70 Billion |
| Cost of Revenue | €9.02 Billion | €9.05 Billion | €8.56 Billion | €9.55 Billion | €8.16 Billion |
| Gross Profit | €23.65 Billion | €22.33 Billion | €21.76 Billion | €19.77 Billion | €16.53 Billion |
| Research & Development | €7.53 Billion | €6.40 Billion | €6.22 Billion | €5.49 Billion | €5.02 Billion |
| SG&A | €9.09 Billion | €11.02 Billion | €9.38 Billion | €8.37 Billion | €7.07 Billion |
| Total Operating Expenses | €24.33 Billion | €25.83 Billion | €22.98 Billion | €22.59 Billion | €19.82 Billion |
| Operating Income | €8.34 Billion | €5.54 Billion | €7.34 Billion | €6.73 Billion | €4.88 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €687.00 Million | €640.00 Million | €725.00 Million | €826.00 Million | €764.00 Million |
| Income Before Tax | €7.40 Billion | €3.48 Billion | €6.06 Billion | €5.63 Billion | €3.60 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €5.72 Billion | €2.58 Billion | €4.93 Billion | €14.96 Billion | €4.38 Billion |
GSK PLC SP. ADR/2 NEW Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GSK PLC SP. ADR/2 NEW's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €61.12 Billion | €59.46 Billion | €59.01 Billion | €60.15 Billion | €79.10 Billion |
| Total Current Assets | €17.51 Billion | €17.00 Billion | €18.64 Billion | €20.77 Billion | €18.67 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €9.00 Million | €21.00 Million | €2.25 Billion | €4.15 Billion | €61.00 Million |
| Net Receivables | €5.91 Billion | €5.56 Billion | €5.91 Billion | €5.45 Billion | €6.25 Billion |
| Inventory | €5.92 Billion | €5.67 Billion | €5.50 Billion | €5.15 Billion | €5.78 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €7.02 Billion | €6.98 Billion | €6.81 Billion | €7.05 Billion | €10.55 Billion |
| Total Liabilities | €45.16 Billion | €46.38 Billion | €46.21 Billion | €50.05 Billion | €57.76 Billion |
| Total Current Liabilities | €21.39 Billion | €21.70 Billion | €21.07 Billion | €22.81 Billion | €23.67 Billion |
| Long-term Debt | €14.02 Billion | €13.70 Billion | €14.15 Billion | €16.19 Billion | €19.76 Billion |
| Net Debt | €13.74 Billion | €12.19 Billion | €14.06 Billion | €16.46 Billion | €19.08 Billion |
| Total Stockholder Equity | €16.38 Billion | €13.67 Billion | €13.35 Billion | €10.60 Billion | €15.05 Billion |
| Retained Earnings | €10.21 Billion | €7.80 Billion | €7.24 Billion | €4.36 Billion | €7.94 Billion |
GSK PLC SP. ADR/2 NEW Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GSK PLC SP. ADR/2 NEW generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €7.74 Billion | €6.55 Billion | €6.77 Billion | €7.40 Billion | €7.95 Billion |
| Capital Expenditures | €2.98 Billion | €2.98 Billion | €2.34 Billion | €2.26 Billion | €2.65 Billion |
| Free Cash Flow | €4.76 Billion | €3.57 Billion | €4.42 Billion | €5.14 Billion | €5.30 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €2.56 Billion | €2.44 Billion | €2.25 Billion | €3.47 Billion | €4.00 Billion |
| Stock-Based Compensation | €374.00 Million | €344.00 Million | €307.00 Million | €346.00 Million | €343.00 Million |
| Depreciation | €2.31 Billion | €2.55 Billion | €2.29 Billion | €2.15 Billion | €2.12 Billion |
| Change in Cash | €-177.00 Million | €599.00 Million | €-468.00 Million | €-546.00 Million | €-1.41 Billion |
GSK PLC SP. ADR/2 NEW Earnings History — EPS Actual vs. Analyst Estimates
Track GSK PLC SP. ADR/2 NEW's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Oct 28, 2026 | — | 1.34 | — |
| Jul 28, 2026 | — | 1.25 | — |
| Apr 29, 2026 | — | 1.16 | — |
| Feb 04, 2026 | 0.16 | 0.62 | -74.19% |
| Oct 29, 2025 | 0.49 | 0.00 | — |
| Jul 30, 2025 | 0.35 | 1.11 | -68.47% |
| Apr 30, 2025 | 0.39 | 0.00 | — |
| Feb 27, 2025 | 0.10 | 0.00 | — |